BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World

Rhea-AI Summary

BeiGene (NASDAQ: BGNE) has opened its flagship U.S. facility in Hopewell, N.J., representing an $800 million investment in biologics manufacturing and clinical R&D capabilities. The 42-acre site features 400,000 square feet of commercial-stage biologic pharmaceutical manufacturing capacity, with room for expansion. This facility enhances BeiGene's ability to produce innovative cancer medicines at scale, reduce costs, and ensure supply chain resiliency.

The company plans to create hundreds of skilled high-tech jobs by the end of 2025. The site includes sustainability measures such as a heating and cooling system using recycled wastewater and is solar-ready. This expansion supports BeiGene's global growth strategy and strengthens its position as a leading oncology innovator with over 30 molecules at clinical or commercial stage.

Positive

• $800 million investment in new U.S. biologics manufacturing and R&D facility
• 400,000 square feet of commercial-stage biologic pharmaceutical manufacturing capacity
• Expansion of late-stage research and clinical development capabilities
• Creation of hundreds of skilled high-tech jobs by the end of 2025
• Enhanced ability to produce innovative cancer medicines at scale
• Potential for cost reduction and improved supply chain resiliency

Negative

• None.

Financial Analyst

BeiGene's $800 million investment in a new U.S. facility is a significant move that underlines the company's commitment to expanding its production capabilities and global footprint. This substantial financial commitment is likely to reassure investors about BeiGene's financial stability and long-term vision. The new facility in New Jersey, a hub for biopharmaceutical innovation, enhances BeiGene's manufacturing and R&D capabilities. This expansion is strategically important as it will help the company meet the growing demand for its oncology drugs. By creating hundreds of high-tech jobs, BeiGene is also likely to benefit from local governmental support and incentives, further strengthening its financial position. The investment could lead to a more resilient supply chain, potentially reducing operational costs and increasing profit margins over time.

Oncology Doctor

From a healthcare perspective, BeiGene's new U.S. facility represents a critical advancement in the fight against cancer. The ability to scale up production of innovative cancer treatments means more patients will have access to potentially life-saving medications. The integration of cutting-edge technologies in this facility suggests a focus on high-quality manufacturing processes, which can lead to more effective treatments with fewer side effects. Additionally, the company's robust pipeline, which includes targeted degraders, ADCs and monoclonal antibodies, positions BeiGene at the forefront of oncology innovation. This facility will likely accelerate the clinical development of new therapies, bringing them to market faster and benefiting patients around the globe more quickly.

Market Research Analyst

BeiGene's expansion into New Jersey, a state with a strong biopharmaceutical sector, strategically places the company in a location rich with talent and resources. This move is consistent with the company's long-term strategy to become a leader in oncology. The investment in a state-of-the-art facility not only enhances production capacity but also strengthens BeiGene's market position. The addition of this facility is likely to improve supply chain resilience and reduce dependency on external suppliers, which is important in maintaining consistent product availability. Moreover, BeiGene’s commitment to sustainability in its operations may attract socially responsible investors, thereby expanding its investor base. This strategic positioning will likely boost investor confidence and support the company's stock value.

$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines

HOPEWELL, N.J.--(BUSINESS WIRE)-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the opening of its flagship U.S. facility in Hopewell, N.J., at the Princeton West Innovation Campus, which houses state-of-the-art biologics manufacturing capabilities and a clinical research and development center that further bolster the Company’s differentiated model as an oncology innovator. BeiGene has more than 30 molecules at clinical or commercial stage, and the 42-acre facility provides flexibility to scale production of its innovative medicines today and in the future to meet the needs of patients with cancer.

BeiGene's flagship biologics manufacturing facility and clinical R&D center at the Princeton West Innovation Campus in Hopewell, N.J., is seen. (Photo: Business Wire)

“BeiGene has experienced unprecedented global growth, and the addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities that will further strengthen our differentiated strategy which leverages speed, efficiency and technology to advance quality medicines faster for patients,” said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. “We are proud to be a part of New Jersey’s biopharmaceutical community that is rich in research and development and manufacturing talent. We look forward to deepening our relationships with key regional research institutions as we advance our robust pipeline of next-generation hematology and solid tumor medicines and continue to emerge as a leading global oncology innovator.”

BeiGene’s $800 million investment is the culmination of a three-year project to expand the Company’s integrated manufacturing and research and development footprint in the U.S. BeiGene will create hundreds of skilled high-tech jobs at the site by the end of 2025. New Jersey is a global leader in biopharmaceutical manufacturing and R&D with nine of the top 10 R&D companies in the world having a presence in the state. New Jersey boasts one of the country’s leading biopharmaceutical manufacturing workforces, and its infrastructure and connectivity ensure access to major markets around the world.

“I am thrilled by BeiGene’s contribution to our state’s thriving biopharmaceutical sector,” said Governor Phil Murphy. “The opening of BeiGene’s flagship campus underscores our commitment to fostering innovation and creating high-tech jobs in the Garden State. We look forward to the positive impact BeiGene will have on our economy and the advancements they will bring to cancer treatment. This significant investment highlights New Jersey’s role as a global leader in pharmaceutical manufacturing, research and development. We are proud to support BeiGene’s mission to develop affordable and accessible treatments for cancer patients worldwide.”

The site features approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing capacity with space to expand over time, allowing flexibility as BeiGene’s pipeline continues to mature. The facility adds to BeiGene’s late-stage research and clinical development capabilities, which have enabled the Company’s fast rise to global oncology leadership. BeiGene has built one of the industry’s deepest and most compelling oncology pipelines, addressing 80 percent of the world’s cancers with innovative modalities such as targeted degraders and antibody drug conjugates (ADCs), in addition to monoclonal antibodies and traditional small molecules. The new facility builds on BeiGene’s existing capabilities, enabling the Company to produce at scale, thereby reducing costs, ensuring supply chain resiliency, avoiding global disruptions, protecting capacity and rapidly adapting to the latest innovative modalities.

“I am excited to welcome BeiGene to Hopewell Township. BeiGene’s new cutting-edge pharmaceutical facility represents a significant investment in our community’s future. The life-saving medicines made right here in Hopewell will not only enhance global cancer treatment, but will also create good-paying, high-tech jobs and strengthen our local economy,” said Hopewell Township Mayor Courtney Peters-Manning. “We look forward to the company’s continued success in Hopewell Township.”

BeiGene recognizes that human health and the health of the planet are intrinsically linked, and the Company is committed to reducing our environmental impact. For this reason, the Company has invested in sustainability measures both in the buildings and surrounding 42 acres, including a heating and cooling system that uses recycled wastewater from the onsite wastewater treatment plant for the cooling towers. The site also is solar-ready in line with our longer-term sustainability plan. More details on the facility, including multimedia assets, are available online at: https://www.beigene.com/hopewell.

About BeiGene

BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the ability of the Hopewell facility to expand and scale the Company’s strength around the world; BeiGene’s ability to deepen relationships with key regional research institutions; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240723282527/en/

Investors:

Liza Heapes

+1 857-302-5663

ir@beigene.com

Media:

Kyle Blankenship

+1 667-351-5176

media@beigene.com

To access BeiGene media resources, please visit our News & Media site.

Source: BeiGene, Ltd.

FAQ

What is the size of BeiGene's investment in the new Hopewell, N.J. facility?

BeiGene has invested $800 million in its new flagship U.S. facility in Hopewell, N.J.

How many square feet of manufacturing capacity does the new BeiGene facility have?

The new BeiGene facility features approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing capacity.

How many jobs will BeiGene create at the new Hopewell facility by 2025?

BeiGene plans to create hundreds of skilled high-tech jobs at the Hopewell site by the end of 2025.

What sustainability features are included in BeiGene's new Hopewell facility?

The facility includes a heating and cooling system that uses recycled wastewater from the onsite treatment plant for cooling towers, and the site is solar-ready for future sustainability plans.

How many molecules does BeiGene (BGNE) have at clinical or commercial stage?

BeiGene has more than 30 molecules at clinical or commercial stage.